Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report
Keywords:COVID-19 Vaccines, Guillain-Barre Syndrome
Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the aforementioned vaccine.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.
JoNMC applies the Creative Commons Attribution (CC BY) license to works we publish. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited.